Spermicide effects questioned by FDA panel

Area of Science:

• Reproductive Health
• Contraception Efficacy
• Public Health

Background:

• Spermicides have been available since 1950 without rigorous efficacy studies.
• Current evidence on spermicide effectiveness is limited and based on flawed historical research.
• The US Food and Drug Administration (FDA) is reviewing current labeling and consumer guidance.

Purpose of the Study:

• To evaluate the effectiveness of available spermicidal contraceptives.
• To determine if specific formulations (gel, foam, suppository, film) offer differential protection.
• To assess the need for updated warnings and consumer information regarding spermicide use.

Main Methods:

• A scientific panel reviewed existing, albeit limited, data on spermicide performance.
• Discussions included the timing of spermicide application relative to intercourse.
• Plans for a new National Institutes of Health (NIH) study comparing spermicide brands were noted.

Main Results:

• Spermicides are more effective than no contraception, but precise effectiveness rates are unknown.
• Reported pregnancy rates for sole spermicide users range widely from 9% to 57% annually.
• Optimal usage timing may be as early as 30 minutes before intercourse.

Conclusions:

• There is insufficient data to recommend specific spermicide formulations.
• Spermicides may require updated labeling to reflect lower efficacy compared to other methods.
• Potential risks include vaginal irritation and possibly increased HIV transmission risk; however, protection against gonorrhea and chlamydia is suggested.